Monopar Therapeutics Inc Asset Resilience Ratio
Monopar Therapeutics Inc asset resilience ratio. Monopar Therapeutics Inc (MNPR) has an Asset Resilience Ratio of 60.41% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MNPR days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Monopar Therapeutics Inc (2021–2025)
Asset resilience ratio of Monopar Therapeutics Inc from 2021 to 2025. This chart shows how Monopar Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Monopar Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Monopar Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Monopar Therapeutics Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $81.54 Million | 60.41% |
| Total Liquid Assets | $81.54 Million | 60.41% |
Asset Resilience Insights
- Very High Liquidity: Monopar Therapeutics Inc maintains exceptional liquid asset reserves at 60.41% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Monopar Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Monopar Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Monopar Therapeutics Inc Asset Resilience Ratio by Year (2021–2025)
Monopar Therapeutics Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Monopar Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.83% | $78.57 Million | $140.72 Million | +31.95pp |
| 2024-12-31 | 23.88% | $14.40 Million | $60.29 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $7.35 Million | -- |
| 2022-12-31 | 37.30% | $4.93 Million | $13.23 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $20.52 Million | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more